{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:11:43Z","timestamp":1791310303304,"version":"4.3.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,10,20]],"date-time":"2013-10-20T00:00:00Z","timestamp":1382227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00280-013-2320-9","type":"journal-article","created":{"date-parts":[[2013,10,19]],"date-time":"2013-10-19T11:05:03Z","timestamp":1382180703000},"page":"1343-1352","source":"Crossref","is-referenced-by-count":37,"title":["A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours"],"prefix":"10.1007","volume":"72","author":[{"name":"A Cancer Research UK Drug Development Office Phase I clinical trial","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Horsley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Backen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Farmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Halbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Halford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurjees","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gireesh","family":"Kumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff J. M.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Smythe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon C.","family":"Jayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,20]]},"reference":[{"key":"2320_CR1","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/sj.bjc.6605661","volume":"102","author":"K Brookes","year":"2010","unstructured":"Brookes K, Cummings J, Backen A, Greystoke A, Ward T, Jayson GC, Dive C (2010) Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br J Cancer 102:1524\u20131532","journal-title":"Br J Cancer"},{"key":"2320_CR2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/oxfordjournals.annonc.a010574","volume":"7","author":"J Cummings","year":"1996","unstructured":"Cummings J, Langdon SP, Ritchie AA, Burns DJ, Mackay J, Stockman P, Leonard RC, Miller WR (1996) Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3\u2032,5\u2032-monophosphate in breast cancer patients and xenograft bearing mice. Ann Oncol 7:291\u2013296","journal-title":"Ann Oncol"},{"key":"2320_CR3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.bjc.6603220","volume":"95","author":"J Cummings","year":"2006","unstructured":"Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, Dive C (2006) Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 95:42\u201348","journal-title":"Br J Cancer"},{"key":"2320_CR4","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/sj.bjc.6602363","volume":"92","author":"J Cummings","year":"2005","unstructured":"Cummings J, Ward TH, Lacasse E, Lefebvre C, St-Jean M, Durkin J, Ranson M, Dive C (2005) Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 92:532\u2013538","journal-title":"Br J Cancer"},{"key":"2320_CR5","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1021\/jm9008339","volume":"52","author":"PJ Dilda","year":"2009","unstructured":"Dilda PJ, Decollogne S, Weerakoon L, Norris MD, Haber M, Allen JD, Hogg PJ (2009) Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol. J Med Chem 52:6209\u20136216","journal-title":"J Med Chem"},{"key":"2320_CR6","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/jnci\/dji316","volume":"97","author":"PJ Dilda","year":"2005","unstructured":"Dilda PJ, Don AS, Tanabe KM, Higgins VJ, Allen JD, Dawes IW, Hogg PJ (2005) Mechanism of selectivity of an angiogenesis inhibitor from screening a genome-wide set of Saccharomyces cerevisiae deletion strains. J Natl Cancer Inst 97:1539\u20131547","journal-title":"J Natl Cancer Inst"},{"key":"2320_CR7","doi-asserted-by":"crossref","first-page":"35428","DOI":"10.1074\/jbc.M804470200","volume":"283","author":"PJ Dilda","year":"2008","unstructured":"Dilda PJ, Ramsay EE, Corti A, Pompella A, Hogg PJ (2008) Metabolism of the tumor angiogenesis inhibitor 4-(N-(S-Glutathionylacetyl)amino)phenylarsonous acid. J Biol Chem 283:35428\u201335434","journal-title":"J Biol Chem"},{"key":"2320_CR8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1535-6108(03)00109-0","volume":"3","author":"AS Don","year":"2003","unstructured":"Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S, Creighton B, Flynn E, Folkman J, Hogg PJ (2003) A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 3:497\u2013509","journal-title":"Cancer Cell"},{"key":"2320_CR9","unstructured":"Ellerhorn M (1997) Ellenhorn\u2019s Medical Toxicology: diagnosis and treatment of human poisoning,. Williams & Wilkins"},{"key":"2320_CR10","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/annonc\/mdn014","volume":"19","author":"A Greystoke","year":"2008","unstructured":"Greystoke A, Cummings J, Ward T, Simpson K, Renehan A, Butt F, Moore D, Gietema J, Blackhall F, Ranson M, Hughes A, Dive C (2008) Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol 19:990\u2013995","journal-title":"Ann Oncol"},{"key":"2320_CR11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","volume":"86","author":"D Hanahan","year":"1996","unstructured":"Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353\u2013364","journal-title":"Cell"},{"key":"2320_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-4274(02)00084-X","volume":"133","author":"MF Hughes","year":"2002","unstructured":"Hughes MF (2002) Arsenic toxicity and potential mechanisms of action. Toxicol Lett 133:1\u201316","journal-title":"Toxicol Lett"},{"key":"2320_CR13","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/0008-5472.CAN-03-2455","volume":"64","author":"G Kramer","year":"2004","unstructured":"Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, Marberger M, Biven K, Shoshan MC, Linder S (2004) Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64:1751\u20131756","journal-title":"Cancer Res"},{"key":"2320_CR14","volume-title":"Handbook on the toxicology of metals","author":"F Nordberg","year":"2007","unstructured":"Nordberg F, Nordberg Friberg ML (2007) Handbook on the toxicology of metals. AP\/Elsevier, Amsterdam"},{"key":"2320_CR15","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-133-11-200012050-00012","volume":"133","author":"K Ohnishi","year":"2000","unstructured":"Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Takeshita A, Sugiyama S, Satoh H, Terada H, Ohno R (2000) Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 133:881\u2013885","journal-title":"Ann Intern Med"},{"key":"2320_CR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1475-2867-12-11","volume":"12","author":"D Park","year":"2012","unstructured":"Park D, Chiu J, Perrone GG, Dilda PJ, Hogg PJ (2012) The tumour metabolism inhibitors GSAO and PENAO react with cysteines 57 and 257 of mitochondrial adenine nucleotide translocase. Cancer Cell Int 12:11","journal-title":"Cancer Cell Int"},{"key":"2320_CR17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.mam.2009.12.005","volume":"31","author":"D Park","year":"2010","unstructured":"Park D, Dilda PJ (2010) Mitochondria as targets in angiogenesis inhibition. Mol Aspects Med 31:113\u2013131","journal-title":"Mol Aspects Med"},{"key":"2320_CR18","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s11095-011-0584-5","volume":"28","author":"EE Ramsay","year":"2011","unstructured":"Ramsay EE, Hogg PJ, Dilda PJ (2011) Mitochondrial metabolism inhibitors for cancer therapy. Pharm Res 28:2731\u20132744","journal-title":"Pharm Res"},{"key":"2320_CR19","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","volume":"89","author":"ZX Shen","year":"1997","unstructured":"Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354\u20133360","journal-title":"Blood"},{"key":"2320_CR20","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJM199811053391901","volume":"339","author":"SL Soignet","year":"1998","unstructured":"Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341\u20131348","journal-title":"N Engl J Med"},{"key":"2320_CR21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"2320_CR22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jmri.1880070113","volume":"7","author":"PS Tofts","year":"1997","unstructured":"Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7:91\u2013101","journal-title":"J Magn Reson Imaging"},{"key":"2320_CR23","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1158\/1078-0432.CCR-08-2984","volume":"15","author":"AM Tsimberidou","year":"2009","unstructured":"Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R (2009) A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res 15:4769\u20134776","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"2320_CR24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.6-suppl_2-3","volume":"6","author":"S Waxman","year":"2001","unstructured":"Waxman S, Anderson KC (2001) History of the development of arsenic derivatives in cancer therapy. Oncologist 6(Suppl 2):3\u201310","journal-title":"Oncologist"},{"key":"2320_CR25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood.V98.2.266","volume":"98","author":"P Westervelt","year":"2001","unstructured":"Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, DiPersio JF (2001) Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98:266\u2013271","journal-title":"Blood"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2320-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2320-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2320-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T06:19:57Z","timestamp":1596694797000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2320-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,20]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2320"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2320-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,20]]}}}